Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CG-0255 by Shanghai CureGene Pharmaceutical for Ischemic Stroke: Likelihood of Approval
CG-0255 is under clinical development by Shanghai CureGene Pharmaceutical and currently in Phase II for Ischemic Stroke. According to GlobalData,...
CG-0255 by Shanghai CureGene Pharmaceutical for Acute Coronary Syndrome: Likelihood of Approval
CG-0255 is under clinical development by Shanghai CureGene Pharmaceutical and currently in Phase II for Acute Coronary Syndrome. According to...
CG-0255 by Shanghai CureGene Pharmaceutical for Myocardial Infarction: Likelihood of Approval
CG-0255 is under clinical development by Shanghai CureGene Pharmaceutical and currently in Phase II for Myocardial Infarction. According to GlobalData,...